尿核基质蛋白22在膀胱癌诊断中的意义

Significance of Urinary Matrix Protein 22 in the Diagnosis of Bladder Cancer

目的 探讨尿核基质蛋白22（NMP22）在膀胱癌早期诊断中的价值及其临床意义.方法 收集2015年1月—2016年12月通过膀胱镜活检或手术病理确诊的膀胱癌患者70例,选择同期进行NMP22检测的120名健康体检者为对照组.所有研究对象均留取晨清洁中段尿50 mL,收集尿液2 h内采用NMP22试剂盒（胶体金法）进行检测.比较膀胱癌组与对照组NMP22阳性表达的差异,分析膀胱癌不同病理特征NMP22阳性表达的差异.结果 初发膀胱癌、复发膀胱癌NMP22的阳性率分别为62.86％、40.00％,与对照组NMP22的阳性率（5.00％）差异有统计学意义.而初发膀胱癌与复发膀胱癌之间差异无统计学意义.70例膀胱癌中病理分级G1、G2和G3级的NMP22阳性率分别为32.43％、55.56％和100.00％,三者之间差异有统计学意义.不同临床分期的NMP22阳性表达差异有统计学意义.NMP22阳性率在不同浸润情况之间差异无统计学意义.结论 尿NMP22可作为膀胱癌早期诊断的一个无创性标志物.

Objective To explore the clinical value of urinary nuclear matrix protein 22 （NMP22） in the diagnosis and follow-up of bladder cancer. Methods Urinary samples were collected from 70 pathologically proven bladder cancer patients and 120 cases of healthy people. Colloidal gold method was employed to measure the urinary NMP22 expression. We compared positive expression between bladder cancer group and control group, and the expression of NMP22 between different clinical pathological parameters in bladder cancer group. Results The positive rates of NMP22 in first and recurrent bladder cancer were 62.86% and 40.00% respectively, and the positive rate （5.00%） of the control group was statistically different. There was no significant difference between the first and recurrent bladder cancer. The NMP22 positive rates of G1, G2 and G3 levels in 70 cases of bladder cancer were 32.43%, 55.56% and 100.00% respectively. The differences were statistically significant between them. And there were statistical differences in NMP22 positive expression of different clinic stages. However, there was no significant difference in the positive rate of MMP22 between different infiltration conditions. Conclusion Urinary NMP22 may serve as a noninvasive biomarker of diagnosis in bladder cancer.